KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to 3327.57%.

  • Recursion Pharmaceuticals' EBITDA Margin fell 29601100.0% to 3327.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 1656.17%, marking a year-over-year decrease of 10675500.0%. This contributed to the annual value of 814.09% for FY2024, which is 287600.0% down from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' EBITDA Margin is 3327.57%, which was down 29601100.0% from 916.75% recorded in Q2 2025.
  • Recursion Pharmaceuticals' EBITDA Margin's 5-year high stood at 367.46% during Q3 2024, with a 5-year trough of 4042.41% in Q4 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' median EBITDA Margin value was 908.36% (recorded in 2023), while the average stood at 1281.17%.
  • Per our database at Business Quant, Recursion Pharmaceuticals' EBITDA Margin skyrocketed by 293818100bps in 2021 and then crashed by -31340500bps in 2024.
  • Recursion Pharmaceuticals' EBITDA Margin (Quarter) stood at 2564.55% in 2021, then surged by 83bps to 445.91% in 2022, then crashed by -104bps to 908.36% in 2023, then plummeted by -345bps to 4042.41% in 2024, then grew by 18bps to 3327.57% in 2025.
  • Its EBITDA Margin stands at 3327.57% for Q3 2025, versus 916.75% for Q2 2025 and 1297.85% for Q1 2025.